Drug Trial Radar · NCT04145258
Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
768
Planned (sponsor's estimate)
Start
Feb 7, 2021
Primary completion
Sep 23, 2026
Study completion Sep 26, 2026
Sponsor
- Lead sponsor
- ANRS, Emerging Infectious DiseasesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- European Union; European and Developing Countries Clinical Trials Partnership (EDCTP)
- First posted
- Oct 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
INTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial assessing the efficacity of two interventions to reduce mortality from tuberculous meningitis (TBM) in adolescents and adults with or without HIV-infection in sub-Saharan Africa: * Intensified TBM treatment with high-dose rifampicin and linezolid, compared to WHO standard TBM treatment. * Aspirin, compared to not receiving aspirin. The trial will be open-label for anti-TB treatment and placebo-controlled for aspirin treatment.
Conditions
- Tuberculous Meningitis
Interventions
AspirinDrug
Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
Placebo of aspirinDrug
Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
WHO TBM treatmentDrug
2 months of (R-H-Z-E) + 7 months of (R-H)
Intensified TBM treatmentDrug
2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of all-cause deathTime frame: Up to 40 weeks
Locations
13 sites in 4 countries. Site status is shown where the registry gives one.
Cocody University Hospital
Abidjan, Côte d’Ivoire · Not yet recruiting
Treichville University Hospital
Abidjan, Côte d’Ivoire · Recruiting
Yopougon University Hospital
Abidjan, Côte d’Ivoire · Not yet recruiting
University Hospital Joseph Raseta Befelatanana
Antananarivo, Madagascar · Recruiting
University Hospital Tambohobe
Fianarantsoa, Madagascar · Recruiting
Morafeno University Hospital
Toamasina, Madagascar · Not yet recruiting
Kayelitsha District Hospital
Cape Town, South Africa · Recruiting
Mitchells Plain Hospital
Cape Town, South Africa · Recruiting
New Somerset Hospital
Cape Town, South Africa · Recruiting
Dora Nginza Hospital
Port Elizabeth, South Africa · Recruiting
Livingstone and PE Central Hospitals
Port Elizabeth, South Africa · Recruiting
Mbarara Regional Reference Hospital
Mbarara, Uganda · Recruiting
Regional Reference Hospital of Kabale
Mbarara, Uganda · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.